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Abstract
Nanovaccines introduced a new dimension to prevent or cure diseases in an efficient and sustained manner. Various polymers have been used
for the drug delivery to increase the therapeutic value with minimal side effects. Thus the present study incorporates both nanotechnology and
polymers for the drug delivery. Poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) was incorporated with the rabies whole attenuated viral
antigen using double emulsion (W/O/W) method and characterized by Scanning Electron Microscopy (SEM) and Atomic Force Microscopy
(AFM). Chitosan-PEG nanoparticles incorporated with the rabies whole attenuated virus antigen (CS-PEG NP-RV Ag.) were prepared using Ionic
Gelation method. The CS-PEG NP-RV Ag. was surface modified with biocompatible polymers such as Acacia, Bovine Serum Albumin (BSA),
Casein, Ovalbumin and Starch by Ionic Gelation method. The morphology was confirmed by SEM and Transmission Electron Microscopy (TEM).
The surface modification was confirmed by Fourier Transform Infrared Spectroscopy (FTIR), Zeta potential. The size distribution of CS-PEG-RV
Ag. and surface modified CS-PEG-RV Ag. by respective biocompatible polymers was assessed by Zetasizer. Release profile of both stabilized
nanoparticles was carried out by modified centrifugal ultrafiltration method which showed the sustained release pattern of the Rabies Ag. Immune
stimulation under in-vitro condition was studied using rosette assay and phagocytosis assay. In-vitro toxicity using human blood and genotoxicity
using human blood DNA was also studied to assess the toxicity of the nanoformulations. The results of these studies infer that PLGA-b-PEG
nanoparticles, CS-PEG and surface modified CS-PEG nanoparticles may be an efficient nanocarrier for the RV Ag. to elicit immune response
sustainably with negligible toxic effect to the human system.
© 2016 Tomsk Polytechnic University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Rabies is the zoonotic disease (a disease transmitted from
animals to humans) caused by the rabies virus of genus
Lyssavirus, says the World Health Organization (WHO). In
several countries, dogs, raccoon dogs, and foxes are considered
to be a major vector for rabies [1].
This disease causes acute inflammation on the brain of the
infected mammal which leads to death. The disease is ranked
endemic on all continents with the highest case incidence in
Asia and Africa; it threatens potentially over 3 million people
[2].
In 1958, Kissling reported the propagation of the rabies
vaccine in hamster cell cultures [3]. This led to the propagation
of the virus in cell cultures. Now the virus is generated in chick
embryos and attenuated using formaldehyde for vaccination
purposes. In the initial stage, the ‘vaccination-challenge assay’
is widely used for batch release of inactivated rabies vaccine for
veterinary use as it attempts to use serological assay [4]. Vac-
cination against rabies provides immunity to the disease in
pre-exposure and postexposure prophylaxis.
Nanovaccines consist of nano-scale based particles attached
or formulated with components to which an immune response
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is desired. Nanovaccines are efficient than the conventional
vaccines as they induce the humoral and cell-mediated response
[5]. With the help of nanotechnology, non-invasive vaccination
can be provided effectively such as oral vaccination for invasive
vaccination techniques as it elicits cell-mediated immunity and
nasal vaccination technique gives rise to systemic humoral,
cellular responses, local and distal secretory immune responses
thus making mucosal lining less vulnerable to infection [6,7].
Efficient deliveries in the targeted tissues are achieved through
nanotechnology [8]. Nanovaccines have evinced the ability for
a number of infectious pathogens, including HIV, malaria,
tuberculosis, and hepatitis C.
Nanoparticles are the good candidates to act as an adjuvant
when compared to the largely used adjuvant, alum [9]. Physi-
cochemical properties, such as particle size, influence the
movement of the nanoparticle to travel through the lymphatic
and accumulate in lymph node-resident dendritic cells.
Nanoparticles used in vaccine formulations increase the immu-
nogenicity and protect it from its loss and thus act as an adju-
vant. Nanovaccines are dreamt to formulate vaccines that
require needle-less administration, have long shelf life, are less
temperature dependent, have sustained immunogenicity and are
one-time dose. This study was done with the view that biopoly-
mers have the potential to increase the therapeutic value of drug
delivery with minimal side effects. For the preparation of the
nano polymer conjugate double emulsion method and ionic
gelation method were used. In vitro toxicity using human blood
and genome toxicity were also performed.
2. Materials and methods
2.1. Preparation of poly(D,L-lactic-co-glycolic
acid)-poly(ethylene glycol) nanoparticles incorporated rabies
whole attenuated virus antigen
2.1.1. Chemicals and reagents
Poly (D,L-lactic-co-glycolic acid) (50:50) 38,000–
54,000 mol. Wt. with terminal carboxyl group (PLGA carbox-
ylate); Dichloromethane (DCM) (both were purchased from
Sigma Aldrich). Heterobifunctional PEG (amine-PEG-
carboxylate) at molecular weight of 3400 g/mol (NOF Corpo-
ration, Tokyo, Japan) is stored in dark at −20 °C and N,N-
diisopropylethylamine (DIEA) (Sigma-Aldrich). Conjugation
crosslinkers: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC) is stored in dark at −20 °C;
N-hydroxysuccinimide (NHS) is stored at 4 °C (both from
Pierce, Rockford, IL). Poly(vinyl alcohol) (PVA) (88% hydro-
lyzed, ∼22 kDa, Fisher), Methanol (Rankem). All the chemicals
were of analytical grade and highly purified.
2.1.2. Synthesis of PLGA-b-PEG polymer
There are two ways to produce PLGA-b-PEG diblock
copolymers. The conjugation of PLGA homopolymer with a
carboxylate end group using EDC and NHS as conjugation
crosslinkers method was preferred in this study over melt or
solution copolymerization in the presence of monomethoxy-
PEG using stannous octoate as a catalyst due to technical easi-
ness and high yield preferences. The modified method is
described below [10].
250 mg of PLGA-carboxylate was first dissolved in 1–2 mL
of DCM. NHS (3.0 mg) is dissolved in 4.8 mg of EDC in 1 mL
of DCM. The PLGA-carboxylate solution was added to the
NHS/EDC solution and gentle stirring was carried out in a
magnetic stirrer to form PLGA-NHS. Precipitation of PLGA-
NHS was done with 20 mL of methanol washing solvent by
centrifugation at 3000 rpm for 10 min and residual EDC/NHS
was removed. Washing and centrifugation were done twice to
ensure purity of the resultant PLGA-NHS. The PLGA-NHS
pellet is dried to remove the residual methanol. After drying
PLGA-NHS (246 mg) was dissolved in 4 mL of DCM followed
by the addition of amine-PEG-carboxylate and DIEA (1:1)
mmol. The mixture solution was incubated under stirring at
600 rpm for 24 hours at room temperature. The resultant
PLGA-b-PEG block copolymer was precipitated with methanol
wash and centrifuged at 3000 rpm for 10 min to remove
the unreacted PEG. The PLGA-b-PEG polymer result was
lyophilized.
2.1.3. Synthesis of PLGA-b-PEG NP-rabies whole attenuated
viral antigen
The modified double emulsion-solvent evaporation method
was used for the preparation of PLGA-b-PEG NP-rabies whole
attenuated viral antigen. The rabies whole attenuated viral
antigen (100 μL) and PLGA-b-PEG polymer (100 mg) were
added with DCM (2 mL) and mixed. Further, the solution was
sonicated using Probe sonicator at 20 W for one minute. The
emulsion occurred was precipitated with PVA (50 mL of 0.1
w/v). Further, it is sonicated at 20 W, 1 min to form W/O/W
emulsion. The emulsion is stirred at 200 rpm, 2 h. The resultant
PLGA-b-PEG-rabies whole attenuated viral antigen was centri-
fuged for 3000 rpm, 15 min and washed with deionized water.
It was recovered and suspended in PBS buffer for a short time
storage.
2.2. Synthesis of chitosan-PEG NP-rabies whole attenuated
viral antigen and functionalization of the conjugate with
biocompatible polymers
2.2.1. Chemicals and reagents
Chitosan (CS) (48 kDa, Primex Co, Iceland), cross linker
Sodium Tripolyphosphate (STPP); Acetic Acid (Sigma
Aldrich), rabies whole attenuated viral antigen with potency
≥2.5 I.U. (Rabipur, Novartis vaccine). Acacia; Bovine Serum
Albumin (BSA); Casein; Starch; Ovalbumin (were purchased
from Ranken). All the chemicals were of analytical grade and
highly pure.
2.2.2. Synthesis of CS NP-PEG-rabies whole attenuated viral
antigen
The method followed was the modified method of inotropic
gelation using STTP as cross linker [11]. CS (25 mg) was taken
and acetic acid (250 μL) was added to it. To this mixture deion-
ized water (75 mL) containing PEG (60 μL) rabies whole
attenuated viral antigen was added and stirred (3–4 h). The
resultant cloudy suspension was centrifuged at 10,000 rpm for
15 min and sonication was done at 20 W at 5 min to recover CS
NP-PEG-rabies whole attenuated viral antigen.
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2.2.3. Synthesis of CS-PEG NP-rabies whole attenuated viral
antigen functionalized with biocompatible polymers
The similar method was followed for functionalization of the
CS NP-PEG-rabies whole attenuated viral antigen. For each
functionalization each biocompatible polymers (Acacia, BSA,
Casein, Starch, and Ovalbumin) was added in 1:1 ratio to the
PEG concentration used for the preparation of CS-PEG-RV Ag.
After overnight stirring, centrifugation (10,000 rpm for 15 min)
and sonication (20 W, 5 min) were done to recover the poly-
meric nanoparticle functionalized with different biocompatible
polymers incorporated Rabies whole attenuated viral antigen.
2.3. Stability study
The method followed for this study was the modified method
of Miles et al. [12]. PLGA-b-PEG NP-RV Ag and CS-PEG
NP-RV Ag were prepared and stored at 100 °C for one month to
assess the structural and storage stability. Antigen stability for
CS-PEG NP-RV Ag. and PLGA-b-PEG NP-RV Ag. was
revealed by SDS-PAGE method of Laemmli [13]. A clean and
rectangular plate was assembled and kept in vertical position by
placing it in a gel casting stand. The separating gel mixture was
prepared and poured into glass plates uniformly without any
leakage. After polymerization of the separating gel, the stacking
gel prepared was poured over it and the comb was inserted
gently. The set up was left for some time to the gel to polym-
erize completely. 50 μL of isolated commercially purchased
rabies Ag. (Rabipur, Novartis vaccine), 50 μL of PLGA-b-PEG
NP-RV Ag. and 50 μL of CS-PEG NP-RV Ag. was mixed with
the sample solubilizing buffer (1:1) and the mixture was boiled
at 950 °C in a water bath for 5–10 minutes. The samples along
with the standard protein marker (29 kDa–205 kDa) were
loaded in the respective wells. The gel was electrophoresed at
50–100 V for 3–4 hours. After the electrophoresis, the gel was
placed in Coomassie blue stain solution for 1 h and washed
thoroughly with distilled water. The stained gel was placed in
destaining solution and washed with distilled water and 20 mL
of the de-staining solution with 20 mL of distilled water was
added and kept overnight incubation. The samples fractioned
into bands were observed and their molecular weights were
determined using the standard marker used.
2.4. Characterizations
2.4.1. Characterization of PLGA-b-PEG polymer and
PLGA-b-PEG NP-whole attenuated RV Ag.
2.4.1.1. Morphology. The surface morphology of the free and
the incorporated nanoparticles were characterized by Scanning
Electron Microscopy (SEM). The samples were sputtered with
Palladium Gold for 30 s under Ploarum Machine (BAC-TEC
Model SCDOO5 Switzerland). Afterwards SEM was per-
formed with Carl Zeiss Super 55 (Germany) Field emission
SEM with the detector at 15 kV. The magnification was set at
65,000. Samples for Atomic Force Microscopy measurements
(AFM) were drop casted on atomically flat mica sheet and
imaged. AFM was done with NTMDT (Ireland).
2.4.2. Characterization of CS-PEG NP-rabies whole
attenuated viral antigen (RV Ag.) and CS-PEG
NP-functionalized with various biocompatible with various
incorporated whole attenuated RV Ag.
2.4.2.1. Fourier transform infrared spectroscopy (FTIR).
Initial characterization of the nanoparticles was done with
Fourier Transform Infrared Spectroscopy (PerkinElmer Spec-
trum version 10.4.00) for free CS NP-PEG; CS NP-PEG
biocompatible polymers and CS NP-PEG-rabies whole attenu-
ated viral antigen; CS NP-PEG-biocompatible polymers-rabies
whole attenuated viral antigen to confirm the surface modifi-
cation. Characterization was performed by recording the absor-
bance of the samples in the frequency range of 4000 cm−1 to
400 cm−1 with the resolution of 4 cm−1. The samples were pel-
letized with KBr before commencing the spectroscopy.
2.4.2.2. Morphology, particle size and ζ potential. The surface
morphology of the free and the incorporated CS nanoparticles
was characterized by Scanning Electron Microscopy (SEM).
The samples were sputtered with Palladium Gold for 30 s under
Ploarum Machine (BAC-TEC Model SCDOOS Switzerland).
Afterwards SEM was performed with Carl Zeiss Super 55
(Germany) Field emission SEM with detector at 15 kV. The
magnification was set at 65,000. Transmission Electron Micros-
copy was done to get the distinct clear morphology of the
nanoparticles. The samples were dispersed in ethanol, sonicated
for 30 s; they were placed in the carbon grid and Field Emission
TEM was done using Hitachi H-7650 (120 kV). The particle
size distribution was analyzed using Dynamic Light Scattering
(DLS) technique. The samples prepared using acetic acid were
dispersed in saline media and measured by DLS (Horiba partica
LA 950) technique. Laser Doppler electrophoresis technique
using the same instrument for the determination of Zeta poten-
tial was also performed.
2.5. % Yield
The prepared PLGA-b-PEG NP-RV Ag., CS-PEG NP-RV
Ag. and surface functionalized CS-PEG-RV Ag. were dried and
yield % was calculated by the formula:
Percentage yield
W
W
=
∗1 100
2
(1)
W1 = weight of the dried nanoparticles recovered; W2 = sum of
the initial dry weight of starting material.
2.6. Entrapment efficiency
Entrapment efficiency of the antigen (Ag) was determined
by filtering a known amount of PEG-PLGA nanoparticles and
surface stabilized CS NP-RV Ag. through a filter membrane
(0.1 μm) to separate the free Ag. The active Ag. was determined
by using the IgG titer. The entrapment efficiency (E) was deter-
mined using the values for the total concentration of RV Ag. in
the system (free + encapsulated, [RV Ag.]0) and that in the
filtrate ([RV Ag.]f) using the equation:
E RV Ag RV Ag f RV Ag% . . .= ( −[ ] [ ]( ) [ ]( )∗0 0 100 (2)
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2.7. Release profile
Release profile of the antigen was performed by the modified
method of centrifugation and ultra-filtration [14]. 50 mg and
100 mg of various surface modified CS NP-PEG incorporated
RV Ag. and PLGA-b-PEG NP incorporated RV Ag. were dis-
solved in 50 mL of 0.2 M/L PBS pH 7.4 containing 0.2% Tween
20, incubated at 37 °C in orbital shaker (REMI) and the respec-
tive readings were taken at predetermined time intervals, i.e., 1,
2, 4, 6, 8, 22, 34, 48, 72, 96, 106 hours for CS NP-PEG
incorporated RV Ag. and for PLGA-b-PEG NP incorporated
RV Ag., the predetermined time interval was every one day for
the first 7 days and thereafter every 7th day up to the 70th day.
At the predetermined time intervals, 2 mL of the solution was
removed and replaced with fresh medium. The sample was
centrifuged 40,000 rpm, 15 min and 10,000 rpm, 30 min
respectively. The supernatant was analyzed by the rabies IgG
titer and OD was taken at 450 nm.
2.8. In-vitro immunogenicity
2.8.1. T-cell rosette formation
In-vitro immunogenicity studies of the CS-PEG NP-RV Ag.
were studied by the T-cell rosette formation (TCRF) assay
method. The modified method of Baehner et al. [15] was used to
perform the assay. In 15 mL centrifugation tube, a buffy coat
layer overlaid on 3 mL of Ficoll 400 was taken. The above
mixture was centrifuged at 4500 rpm for 40 minutes at 100 °C.
Platelets and plasma were discarded carefully such that lym-
phocytes are left. The obtained lymphocytes were transferred to
a sterile centrifuge tube and PBS (1 mL) was added and cen-
trifuged at 4500 rpm for 15 minutes at 100 °C thrice to remove
RBCs. The supernatant was discarded and the pellet was sus-
pended in RPMI media and cultured in T25 suspension culture
flasks incubated at 37 °C under 5% CO2 incubator.
Different concentrations of the test concentration were
mixed with RPMI media (10, 25, 50, 75 and 100 mg/mL) and
added to 12 well plates (pre incubated with T lymphocytes). The
plates were incubated at 370 °C under 5% CO2 incubator for 1
hour. The lymphocytes were mixed with sheep erythrocytes at
the rate of 10:1 ratio after the incubation period. Supernatant
was removed and the pellet was collected and suspended. The
rosette thus obtained was counted in a hemocytometer.
2.8.2. Phagocytic assay
RAW cells suspended in DMEM medium were taken and
plated into 96 well late (4 × 105 cells) per well. The plates
containing the RAW cells were incubated at 37 °C, 5% CO2
incubator. The cells were washed with PBS after the incubation
period is over. The cells were washed with HEPES balanced salt
solution thrice and incubated at room temperature for 15
minutes. Fluorescent micro particle formulations were incu-
bated for 15 minutes at 37 °C. The nanoparticles which were
not phagocytized were removed by washing the cells with cold
PBS. The washed cells were fixed with 10% glutaraldehyde.
Microscopic examination was carried out by the method of Xu
et al. [16] to determine the number of phagocytized cells.
2.9. In-vitro blood compatibility test
2.9.1. PLGA-b-PEG NP, CS-PEG NP and surface modified
CS-PEG nanoparticles incorporated with whole attenuated
RV Ag
To the 5 mL of human blood taken in five vials at different
concentrations, the nanoparticles incorporated with whole
attenuated RV Ag. were added and kept in a shaker (3 h) at
room temperature. The vials are centrifuged for 10,000 rpm for
10 min and tested for hemolysis. The percentage of hemolysis
was determined by the formula of plasma hemoglobin as
follows:
Amount of plasma hemoglobin mg dL A
A A
( )
( )∗
= ∗
− + ∗
2 415
380 450 1000 dilution factor E ∗( )1 655. (3)
where A415, A380, A450 are the absorbance values at 415, 380
and 450 nm, E is the absorptivity value of oxyhemoglobin at
415 nm.
2.10. Genotoxicity
Genotoxicity assay was performed by the modified method
of Namasivayam et al. [1]. The human blood DNA was isolated
by using a standard protocol. To the purified DNA which was
suspended and stored at 20 μg/mL in Tris buffer under pH 7.8
at −20 °C, the aliquots of PLGA-b-PEG-whole attenuated RV
Ag. and surface stabilized CS NP incorporated with whole
attenuated RV Ag. were added and incubated at 37 °C for 24
hours and electrophoresis was done using Tris acetate buffer at
150 A for 30 minutes.
3. Results and discussion
3.1. Structural and storage stability of encapsulated antigen
nano formulation
Antigen incorporated in PLGA-b-PEG NP and CS-PEG NP
was stored at 10 °C for one month. SDS-PAGE was done to
assess the stability by taking the molecular weight as the param-
eter. The molecular weight of the rabies vaccine (commercially
purchased) and the molecular weight of the formulated vaccine
with PLGA-b-PEG NP and CS-PEG NP were exhibited as
66 kDa without any damage or split in the band which reveals
that the formulated antigen is stable. Fig. 1 shows the SDS-
PAGE of Control (C), PLGA-b-PEG NP-RV Ag. (PPR) and
CS-PEG NP-RV Ag. (CPR).
3.2. Characterization
3.2.1. Morphology
3.2.1.1. PLGA-b-PEG polymer and PLGA-b-PEG NP-whole
attenuated RV Ag.
3.2.1.1.1. Scanning electron microscopy. Fig. 2 captured in
the range of 2 μm shows the clear morphology as a film reveals
the structure of polymer (PLGA-b-PEG). Fig. 2 shows the
nanoparticle of the PLGA-b-PEG NP-RV Ag. The size of the
particles ranges between 90 nm and 1.4 μm. The SEM images
confer the micro and nano spheres of PLGA-b-PEG NP-RV Ag.
S28 K. Nivedh et al. /Resource-Efficient Technologies 2 (2016) S25–S38
3.2.1.1.2. Atomic force microscopy (AFM). The Fig. 3A
shows the 3D image and Fig. 3B shows the X section at 216 nm
and evinces that the PLGA-b-PEG has a film like structure.
Fig. 3C and D displays the clear spherical morphology of the
PLGA-b-PEG NP RV antigen with the size range of 80 nm–
400 nm. Fig. 3E and F display the line profile of PLGA-b-PEG
polymer and PLGA-b-PEG NP-RV Ag. respectively. The
roughness of 203.607 nm signifies that the nanoformulation has
the potential to release the antigen in a controlled and sustained
manner.
3.2.2. Fourier transform infrared spectroscopy (FTIR)
3.2.2.1. FTIR studies of free chitosan and functionalized
chitosan with biocompatible polymers. Initial characterization
was done with Fourier Transform Infrared Spectroscopy
(PerkinElmer Spectrum version 10.4.00) for free CS-TTP NP,
CS NP-PEG; CS NP PEG-biocompatible polymers to initially
confirm the surface modification. The spectra of CS-NP are
shown in the Fig. 4A and the spectra of the respective nano
polymers were displayed in the Fig. 4B.
The changes in the position of the peaks of the respective
polymeric nano formulations with respect to the chitosan
nanoparticles were observed to assert the surface modification
of chitosan nanoparticles with respective biocompatible poly-
mers. The 1638.2 spectra seen in CS NP attribute to N—H bond
shifted to 1650 in CSPEG NP. The peaks in the range of 850–
900 cm−1 were the result of saccharide structure of CS [17].
There is also a change in the position of the peak from 3447 to
3380 cm−1 which shows that there are some changes in the
chitosan nanoparticle. An only peak in the range of 1130–
1000 cm−1 clearly indicates that the chitosan is modified with
PEG. Similarly the characteristic range of peaks for the respec-
tive biocompatible polymers reveals that the chitosan is
functionalized with the respective biocompatible polymers.
3.2.2.2. FTIR for CS-PEG-RV Ag. and CS-PEG-RV Ag.
functionalized with biocompatible polymers. The broadening
of the peaks in every FTIR shown in Fig. 5 reveals that the
presence of the hydroxyl bonds attaches or presents promi-
nently along with the other bonds. This shows the incorporation
of the RV Ag. on comparing the peaks absorbed in the free and
incorporated CS NP and surface stabilized CS nanoparticles
clearly. The additional peaks obtained were due to the presence
of respective polymeric coating.
3.2.3. Morphology, particle size and ζ potential
3.2.3.1. Scanning electron microscopy and transmission
electron microscopy. SEM and TEM were done for the
CS-PEG NP-RV Ag. The SEM shows the three dimensional
surface topography of the particles that range around
90–200 nm in size. A characteristic spherical shape for the
CS-PEG-RV Ag. was observed. The TEM micrograph shows
the distinct shape of the particles, its surface modification and
incorporation of the antigen. Refer to Fig. 6A and B.
3.2.4. Particle size distribution
The particle size distribution of the CS-PEG-RV Ag. and
surface modified CSPEG-RV Ag. with various biocompatible
polymers prepared using acetic acid as the solvent through
Ionic gelation method was studied. DLS technique was used for
measuring the hydrodynamic diameter of the particles and for
the determination of particle size distribution. Fig. 7A–F sum-
marizes the results.
3.2.5. Zeta potential
The CS NP are highly positively charged (+40 mV) which
indicates the protonation of NH2 functional groups of glu-
cosamine units to NH3+ ions in acidic media [18]. When it is
dispersed in saline media the charge was reduced to +20 mV.
The presence of high positive charge gives rise to low blood
compatibility. The present study was done to reduce the high
positive charge to low positive charge to make it much better
biocompatible. The changes in the charges with respect to
Fig. 1. Structural and storage stability of encapsulated antigen nano
formulation.
Fig. 2. PLGA-b-PEG polymer and PLGA-b-PEG-RV Ag.
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Fig. 3. (A) 3D Image of PLGA-b-PEG polymer. (B) X section at 216 nm. (C) 3D image of PLGA-b-PEG NP-RV Ag. (D) X Section. (E) Line profile of
PLGA-b-PEG polymer. (F) Line profile of PLGA-b-PEG-RV Ag.
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CS-PEG NP-RV Ag. also confirm the surface medication by
biocompatible polymers. From the obtained values it is also
suggested that CS and surface modified CS incorporated RV
Ag. should be packed as powders (lyophilized) for a long time
stability. The dispersion of the particles in .9% saline induces
the deprotonating process. In this process it is asserted that Cl−
counter ions in saline migrate to the Gouy layer and interacts
with NH3+ groups, resulting in deprotonating which results in
the drop of the charges in ζ potential values [18]. Thus it is
recommended that dispersing with saline media (.9%) before
administration exhibits high biocompatibility (Table 1).
3.3. % Yield
The % of the yield of PLGA-b-PEG NP-RV Ag. CS-PEG
NP-RV Ag. and surface functionalized CS-PEG-RV Ag. was
calculated and tabulated below (Table 2).
3.4. Entrapment efficiency
Entrapment efficiency of the PLGA-b-PEG NP-RV Ag.
and CS-PEG NP and CSPEG NP stabilized with various
biocompatible polymers incorporated with RV Ag. was inves-
tigated using the formula suggested in the methodology. The
results are tabulated below (Table 3).
3.5. In-vitro release profile
3.5.1. In-vitro release profile of PLGA-b-PEG-RV Ag.
In-vitro release profile provides the release of the antigen
from the PLGA-b-PEG NP matrix. The cumulative % release of
antigen at 37 °C in different time intervals was shown in
Fig. 8A–F. The antigen release was found to be 64.9% at the
70th day. From the release profile it is clear that the release of
RV Ag. from the nano-sphere was characterized by initial rapid
Fig. 4. (A) FTIR of CS NP. (B) FTIR for CS-PEG-RV Ag. and CS-PEG-RV Ag. functionalized with biocompatible polymers.
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Fig. 5. TIR of CS-PEG-RV Ag and CS-PEG-RV Ag. functionalized with biocompatible polymers.
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release (Burst release) phase of about 30%. It is assumed that
this burst release is related to drug entrapment near the surface
of the nano spheres [19]. This phase is followed by slow release.
Around 37% antigen release was recorded for the duration of 50
days. This phase is characterized as sustained release phase.
3.5.2. In-vitro release of CS-PEG NP and surface stabilized
CS-PEG NP incorporated with RV Ag.
3.5.2.1. Release kinetics of CS-PEG NP-RV Ag. The in-vitro
release profile of RV Ag. entrapped in CS-PEG NP was per-
formed in 0.2 M PBS at 37 °C. The study records the cumula-
tive % of the antigen release shown in Fig. 8A. The initial burst
release occurred for 8 hours and the release was about 35%. The
release rate slowed down after the first phase of release and
attained equilibrium after 10 hours from the commencement of
the experiment. The cumulative release until the 80th hour was
43% (approx.) and there was a slight burst release (2nd burst) at
the 106th hour. After 106 hours, the amount of antigen released
was around 56%. The two phases of burst release of the antigen
may be due to the diffusion of the antigen that was entrapped
poorly in the matrix of CS-PEG NP while the sustained release
may be due to the diffusion of the antigen from the core of the
matrix [20].
3.5.2.2. Release profile of CS-PEG NP-Acacia-RV Ag. The
in-vitro profile of CS-PEG NP-Acacia-RV Ag. was shown in
Fig. 8B. It was observed that there was a rapid release (about
36%) within 10 hours. After the 10th hour there was a sustained
release pattern until the 80th hour. During this time about 42%
of the antigen was released. At the end of the 106th hour about
55% of the antigen was released cumulatively.
3.5.2.3. Release profile of CS-PEG-BSA-RV Ag. The release
behavior of CS-PEG-BSANP-RV was shown in Fig. 8C. A
slight variation is observed between the 11th hour and 100th
hour. Two clear burst release patterns were seen in this kinetics,
one at the initial period 10 hours and the other at the final 6
hours. 58% of cumulative release was observed after 106 hours.
3.5.2.4. Release kinetics-chitosan-PEG-casein-rabies antigen
conjugate. In the first 9 hours there was a burst release of 33%.
After the 10th hour there was a gradual release of the antigen
from the matrix. There was a sharp burst release after the 100th
hour. Thus a cumulative release of 60% (approx.) of antigen in
106 hours was obtained. The results were plotted and shown in
Fig. 8D.
3.5.2.5. Release kinetics-chitosan-PEG-ovalbumin-rabies
antigen conjugate. The release kinetics of the CS-PEG-
ovalbumin-RV Ag. was profiled in this study and shown in
Fig. 8E.
Fig. 6. (A) SEM-CS-PEG NP-RV Ag. (B) TEM-CS-PEG NP-RV Ag.
Table 1
Zeta potential of nano formulation.
Nanoparticle from AA in saline Potential
1.CPR +3.5
2.CPAR −2.4
3.CPBR −3.6
4.CPCR −6.9
5.CPSR −3.8
6.CPOR −2.1
Table 2
% Yield of polymeric nano spheres.
Polymeric nano spheres Yield %
1. PLGA-b-PEG-RV Ag. 85.79
2. CS-PEG NP 90.83
3. CS-PEG-Acacia NP 88.72
4. CS-PEG-BSA NP 86.44
5. CS-PEG-Casein NP 88.56
6. CS-PEG-Ovalbumin NP 85.07
7. CS-PEG-Starch NP 87.12
Table 3
Entrapment efficiency (%) of polymeric nano spheres.
Polymeric nano spheres Entrapment efficiency (%)
1. PLGA-b-PEG NP 73
2.CS-PEG NP 75.33
3.CS-PEG-Acacia NP 71.21
4.CS-PEG-BSA NP 69.15
5.CS-PEG-Casein NP 69.58
6.CS-PEG-Ovalbumin NP 74.12
7.CS-PEG-Starch NP 70
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The release curve exhibits rapid diffusion of the antigen in
less than 9 hours from the beginning of the study. The gradual
increase in the release of the antigen when compared to the first
9 hours is seen between the 10th hour and 20th hour (5%
approx.). 15% of antigen was released sustainably. From this
matrix, a negligible burst of release was observed at the end of
106 hours. Cumulatively there was a discharge of 64% of
antigen for 106 hours. Thus CS-PEG-ovalbumin NP shows
good sustainable release characteristics.
3.5.2.6. Release profile of CS-PEG-starch-RV Ag. The Fig. 8F
reveals that there is a very little fast diffusion of the antigen at
the end of the phase of the study. The duration of the sustainable
release was lengthier (lasted for 50 hours). There was an initial
burst release of about 37% recorded in less than 10 hours for
this conjugate. CS-PEG-starch evinces itself as one of the best
candidates to serve as a bystander for vaccine delivery.
3.6. In-vitro immunogenicity
3.6.1. T-cell rosette assay
T-cell rosette assay was used to assess the immunological
reaction and to identify the T cells where T cells CD2 surface
protein is bound to a sugar based LFA-m homolog on the
surface of the sheep red blood cell [21]. The number of rosette
Fig. 7. (A) CSPSR size distribution. (B) CSPAR size distribution. (C) CSPBR size distribution. (D) CSPBR size distribution. (E) CSPOR size distribution. (F)
CSPSR size distribution.
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Fig. 8. Release profile. (A) Release profile of PLGA-b-PEG RV Ag. (B) Release profile of CPR. (C) Release profile of CPAR. (D) Release profile of CPBR. (E)
Release profile of CPCR. (F) Release profile of CPSR.
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results for the different concentrations of CS-PEG-RV Ag. was
tabulated below (Table 4).
3.6.2. Phagocytosis assay
Phagocytosis assay was done to find out the number of nano
conjugates phagocytized. This is one of the best techniques to
address the immunogenicity in vitro. The results for the phago-
cytosis assay were tabulated for CS-PEG NP- RV Ag. below
(Table 5).
3.7. In-vitro blood compatibility test
In-vitro blood compatibility test was done to check the
biocompatibility of PLGA-b-PEG NP-RV Ag. and CS-PEG
NP-RV Ag. in terms of hemolysis. No significant hemolysis (no
traces of pale red color in serum) was observed when the human
blood is treated with different concentrations of PLGA-b-PEG
NP-RV Ag. and CSPEG NP-RV Ag. SEM was taken to ensure
that there is no significant hemolysis against the untreated blood
with particles (control) and is shown in Fig. 9. Thus, the results
can be concluded that PLGAb-PEG NP-RV Ag. and CS-PEG
NP-RV Ag. are very biocompatible.
3.8. Genotoxicity
The genotoxicity assay for PLGA-b-PEG NP-RV Ag., CS
NP and surface modified CS NP incorporated RV Ag. was
proceeded by the method discussed in the Methodology section.
The assay with different nanoparticles tested evinces that there
is no clear toxicity at the genomic level in human blood as there
are no fragmentations or degradations. A sharp DNA band was
observed in the tested DNA as in control. This displays that the
nanoparticles are compatible with the human blood DNA. The
results were shown in Fig. 10.
4. Conclusion
The use of biodegradable polymers gives the ability to
control the time, rate of degradation and antigen release [22]. In
this point of view the present study was done. The well-known
biocompatible and degradable polymers – poly(D,L-lactic-co-
glycolic acid) functionalized with poly(ethylene glycol) (PEG)
nanoparticles, chitosan-PEG (CS-PEG) and chitosan-PEG
surface modified nanoparticles with biocompatible polymers
(Acacia, Bovine Serum Albumin, Casein, Ovalbumin and
Starch) were synthesized and loaded with the rabies whole
attenuated viral antigen (RV Ag.) using the modified double
emulsion-solvent evaporation method and the modified ionic
gelation method respectively. The characterization of the nano
formulations using Scanning Electron Morphology (SEM)
showed the characteristic spherical morphology of the
nanoparticles formed. Transmission Electron Microscopy
(TEM) of CS-PEG-RV Ag. revealed the distinct image of the
nano conjugate formed. Fourier Transform Infrared Spectros-
copy (FTIR) studies for the CS-PEG, surface modified
CS-PEG, CS-PEG-RV Ag. and surface modified CSPEG-RV
Ag. confirmed the incorporation of the antigen and surface
modification through the difference in the occurrence of
the peaks among the nano formulations. Zeta size for the
Table 4
Number of rosette concentration (mg/mL).
Concentration (mg/mL) Number of rosettes
10 10
25 28
50 35
75 49
100 60
Table 5
Phagocytosis in %.
Concentration (mg/mL) Phagocytosis (%)
10 38
25 49
50 62
75 76
100 80.7
Fig. 9. (A) Blood cell control. (B) Blood cell test.
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CS-PEG- RV Ag. and surface modified CS-PEG-RV Ag.
revealed the size distribution of the polymeric nano formulation
in saline media. A Zeta potential is a term for electro kinetic
potential in colloidal systems which has a major effect on
various properties of nano drug delivery system [23]. Zeta
potential of the CS-PEG-RV Ag. and surface modified
CS-PEG-RV Ag displayed lower +ve and −ve charges which
show the biocompatibility and confirmation of the surface
modification. Antigen stability study was performed for PLGA-
b-PEGNP-RV Ag. and CS-PEG NP-RV Ag. by keeping the
nano formulations at 100 °C for a month and the structural and
storage stability were confirmed by running SDS-PAGE. In
vitro immunogenicity by T cell rosette assay and phagocytic
assay resulted in 60 T cell rosette for a 100 mg concentration
and 80.7% of phagocytosis for a 100 mg concentration of the
CS-PEG-RV Ag. respectively. In vitro release profile for the
nano formulation showed the pattern of initial burst release in
the starting phase followed by sustained release and another
burst release was observed for CS-PEG NP and surface modi-
fied CS-PEG NP-RV Ag. and only one initial burst release
pattern was observed in PLGA-b-PEG NP-RV Ag. In vitro
toxicity using blood compatibility test for PLGA-b-PEG
NP-RV Ag. and CS-PEG NP-RV Ag. was performed and the
experiment resulted in no significant toxicity. Genotoxicity
assay using human blood for the respective nano formulations
revealed no toxicity. CS-PEG-RV Ag. is thus suggested for
pharmaceutical mass production after the successful clinical
trials.
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